-
A low-protein diet can starve cancer cells and overcome resistance to treatment
Time of Update: 2023-01-06
Researchers found in cells and mice that low-protein diets blocked nutrient signaling pathways that activate major regulators of cancer growth.
Researchers found in cells and mice that low-protein diets blocked nutrient signaling pathways that activate major regulators of cancer growth.
-
A low-protein diet can starve cancer cells and overcome resistance to treatment
Time of Update: 2023-01-06
Researchers found in cells and mice that low-protein diets blocked nutrient signaling pathways that activate major regulators of cancer growth.
Researchers found in cells and mice that low-protein diets blocked nutrient signaling pathways that activate major regulators of cancer growth.
-
SCI ADV: Identifies a specific regulator that promotes breast cancer development
Time of Update: 2022-11-26
27-hydroxycholesterol (27-HC, 27-hydroxy) is the most abundant oxysterol that increases the risk of breast cancer progression, but researchers do not currently know the epigenetic regulation of 27-HC
-
Professor Shi Min: How much impact does PD-L1 detection have on the clinical practice of first-line immunotherapy for gastric cancer
Time of Update: 2022-11-01
According to the 2022 CSCO guidelines for the diagnosis and treatment of gastric cancer, nivolumab combination chemotherapy has been recommended for the whole population with CPS≥5 and CPS<5 or PD-L1 detection5, and this patient has also benefited from advanced first-line treatment with nivolumab combination chemotherapy.
-
Frontier Progress PRODIGE 24 Study 5-Year Follow-up Results Announced! mFOLFIRINOX adjuvant chemotherapy can significantly benefit patients with pancreatic cancer
Time of Update: 2022-10-20
Pancreatic cancer, known as the "king of cancers", often has a poor patient prognosis and is one of the leading causes of cancer-related death worldwide. For resectable and border-resectable pancreati
-
Bristol-Myers Squibb relatlimab for the treatment of melanoma
Time of Update: 2022-10-03
Immune checkpoint inhibitors are a class of cancer immunotherapies that have been approved for 8 drugs, 7 of which have a mechanism similar to the PD-1 inhibitors sintilimab (Xindilizumab) of Eli Lilly and Cinda Biologics, which have been marketed in China under the brand name Tyvyt (Dabosu).
-
ESMO 2022 takes stock of the highlights of early breast cancer
Time of Update: 2022-10-03
brief summaryThe results of many clinical trials of extended therapy after 5 years of AI-assisted endocrine therapy are inconsistent, and GIM4 studies have shown that after 2 to 3 years of amoxifen treatment, adjuvant therapy regimens that extend the use time of letrozole can bring greater benefits to postmenopausal HR+ breast cancer patients; In the NSABP B42 study, the AI treatment group with extended 5 years increased overall DFS by 3.
-
JAMA Dermatol: Does Spironolactone Really Cause Increased Cancer Risk
Time of Update: 2022-04-22
Given this official warning and uncertainty about the potential link between spironolactone use and cancer, the aim of this study was to conduct a systematic review and meta-analysis to synthesize the evidence on cancer risk from spironolactone use .
-
NEJM: The third-generation immune checkpoint comes into play: LAG-3+PD-1, doubles progression-free survival in advanced cancer
Time of Update: 2022-01-23
In this phase II/III double-blind randomized controlled clinical trial, a total of 714 patients with previously untreated advanced melanoma were randomized 1:1 to receive either Relatlimab + Nivolumab combination therapy or Nivolumab monotherapy .
-
How to follow-up treatment for prostate cancer recurrence after MDT curative treatment
Time of Update: 2021-11-05
Special report: Measuring the comprehensive benefits of new endocrine first-line treatment of CRPC patients Professor Zhang mainly reported on three aspects: 1 Enzalutamide is an ideal solution for new hormone therapy (NHT) castration-resistant prostate cancer (CRPC); 2 Older age and high burden of comorbidities are common features of CRPC patients in China.
-
Microchip Bio: Chidamide was approved for marketing in Japan
Time of Update: 2021-09-07
On the 24th, Microchip announced that the company’s partner Huya Bio-International has recently received approval from the Japan Pharmaceuticals and Medical Devices Agency (PMDA) to approve the listing of chidamide for monotherapy in the treatment of relapsed or refractory (R /R) Adult T-cell leukemia (ATL) .
The original innovative drug was approved for listing overseas .
-
Fosun Pharma Holding Subsidiary's Trastuzumab for Injection Obtained Notice of Approval of Supplementary Drug Application
Time of Update: 2021-08-28
On August 17, Fosun Pharma issued an announcement stating that its controlling subsidiary Hanlius Pharmaceuticals had received the "Drug Supplementary Application for Trastuzumab for Injection (trade name: Hanquyou®) issued by the National Medical Products Administration.
-
Reduce the risk of disease progression by 78%, multi-kinase inhibitors receive FDA priority review qualification
Time of Update: 2021-08-15
On August 5, 2021, Exelixis announced that the US FDA has granted its multi-kinase inhibitor cabozantinib (cabozantinib, English trade name Cabometyx) supplementary new drug application (sNDA) priority review qualification for the treatment of 12-year-old and Patients with differentiated thyroid cancer (DTC) above .
-
A number of studies will be unveiled in 2021ASCO Rongchang Biowidicitumumab will be approved soon
Time of Update: 2021-06-30
In August 2020, the listing application for HER2 overexpression of locally advanced or metastatic gastric cancer (including gastroesophageal junction cancer) that has received at least 2 systems of chemotherapy after the treatment of recurrence/metastasis by Vidicizumab was accepted by CDE and became a domestic The first domestic ADC drug reported for production .
-
Reduce the risk of breast cancer recurrence by 42%. Olapali Phase 3 clinical results are positive
Time of Update: 2021-06-16
Today, AstraZeneca and Merck (MSD) jointly announced that the PARP inhibitor Olapali (English trade name Lynparza), jointly developed by the two parties, is used in the treatment of high-risk HER2-negative early stage with germline BRCA mutation (gBRCAm) Positive results were obtained in phase 3 clinical trials of breast cancer .
